SBFM Stock Overview
A pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sunshine Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.36 |
| 52 Week High | US$637.20 |
| 52 Week Low | US$2.11 |
| Beta | -1.04 |
| 11 Month Change | -21.59% |
| 3 Month Change | -22.62% |
| 1 Year Change | -99.58% |
| 33 Year Change | -99.99% |
| 5 Year Change | -99.94% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues
Jan 29Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch
Sep 12Sunshine Biopharma acquires Nora Pharma for C$30M
Oct 20We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth
Aug 08Sunshine Biopharma reports 1H results
Aug 04Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
Apr 17Shareholder Returns
| SBFM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | 2.4% | 2.2% |
| 1Y | -99.6% | 16.2% | 31.7% |
Return vs Industry: SBFM underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: SBFM underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| SBFM volatility | |
|---|---|
| SBFM Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SBFM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SBFM's weekly volatility has decreased from 28% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 44 | Steve Slilaty | sunshinebiopharma.com |
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.
Sunshine Biopharma, Inc. Fundamentals Summary
| SBFM fundamental statistics | |
|---|---|
| Market cap | US$4.72m |
| Earnings (TTM) | -US$4.23m |
| Revenue (TTM) | US$32.96m |
0.1x
P/S Ratio-1.1x
P/E RatioIs SBFM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBFM income statement (TTM) | |
|---|---|
| Revenue | US$32.96m |
| Cost of Revenue | US$22.81m |
| Gross Profit | US$10.14m |
| Other Expenses | US$14.37m |
| Earnings | -US$4.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | 30.78% |
| Net Profit Margin | -12.82% |
| Debt/Equity Ratio | 0% |
How did SBFM perform over the long term?
See historical performance and comparison